BACKGROUND: Fingolimod, an oral immunomodulatory therapy approved to treat multiple sclerosis (MS) is contraindicated in patients with certain cardiac conditions, yet the frequency of these conditions in patients with MS is not known. This study assessed the frequency and economic impact of cardiac conditions among hospitalizations of patients with MS.
M ultiple sclerosis (MS) is a chronic, disabling, and costly disease affecting approximately 400,000 persons in the United States. 1 Symptoms include cognitive dysfunction, lack of coordination, visual disturbances, fatigue, muscle weakness, bowel and bladder problems, and personality changes. [1] [2] [3] Most patients will first present with clinically isolated syndrome, defined as the initial neurological attack caused by the central nervous system, 4 and 80% of those patients will go on to develop relapsing-remitting MS (RRMS). RRMS is the most common type of MS and is characterized by a period of neurologic instability (relapse) followed by a period of neurologic stability. 1, 5 There is currently no cure for MS; treatment focuses on symptom management and reducing the number of relapses with disease-modifying therapies.
Due to diagnosis in early adulthood and the high acquisition of costs of treatment, the economic burden of MS is substantial. 6, 7 The estimated total all-cause medical costs are nearly 5 times higher per year for patients with MS compared with those without MS, with at least 25% of incremental costs attributed to drug therapy. 6 In the United States, it is estimated that the cost per patient per year can exceed $50,000 (2008 U.S. dollars), 8 while the estimated total lifetime cost to a patient is $4.1 million (2010 U.S. dollars). 9, 10 The cost per patient is dependent on many factors, including choice of therapy, the type of MS, disease progression, as well as comorbid conditions. 6, 9 An understanding of the frequency of comorbid conditions is crucial, since certain comorbidities may affect the choice of immunomodulatory therapy. Specifically, fingolimod, the sphingosine 1-phosphate receptor modulator, is contraindicated in patients with recent myocardial infarction
• Certain comorbidities may affect the choice of immunomodulatory therapy in patients with multiple sclerosis (MS). Specifically, fingolimod is contraindicated in patients with certain cardiovascular conditions. • Data on the frequency of the specific cardiac comorbidities from the fingolimod labeling are both limited and mixed.
What is already known about this subject
• Of 136,542 discharges with a diagnosis of MS, 9.2% (n = 12,504) had at least 1 comorbid cardiac condition of interest based on contraindications to fingolimod in the prescribing information.
• Heart failure was the most common of the comorbid cardiac conditions assessed (59.4%), followed by myocardial infarction (17.2%) and occlusion of cerebral arteries (12.4%). Other cardiac conditions accounted for less than 10% of hospital discharges.
• The incremental cost per hospital day was $6,479 for the MS with a cardiac condition of interest cohort.
the objective of this study was to determine the frequency and economic impact of comorbid cardiac conditions among hospitalizations of patients with a diagnosis of MS.
■■ Methods Design and Data Source A retrospective, discharge-level, cohort study was conducted using 2006 to 2010 data from the National Inpatient Sample (NIS), part of the Healthcare Cost and Utilization Project, which is sponsored by the Agency for Healthcare Research and Quality. This dataset was selected because it is the largest allpayer publically available dataset, representing approximately 20% of hospital stays in the United States. 15 The database contains approximately 8 million hospital visits each year, encompassing over 1,000 hospitals in 46 states (2011) . Given that the NIS only includes discharge-level data for hospitalized patients, this study determined the frequency of comorbid cardiac conditions among hospitalizations of patients with MS and did not attempt to assess cardiac comorbidities among all patients with MS.
Cohort Selection
All hospital discharges with an MS diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 340.xx) from January 1, 2006, to December 31, 2010, were identified. Since MS is a lifelong condition, identification was based upon an ICD-9-CM code in any diagnosis field to capture all discharges for patients with MS. Two cohorts were defined: (1) MS with cardiac condition and (2) MS with no cardiac condition ( Figure 1 ). These cohorts were based on the presence or absence, respectively, of at least 1 comorbid cardiac condition in any diagnosis field using the following (MI), unstable angina, stroke, transient ischemic attack, heart failure requiring hospitalization, or Class III/IV heart failure; Mobitz Type II second degree or third degree AV block or sick sinus syndrome unless the patient has a pacemaker; baseline QTc > 500ms; or treatment with Class 1a or Class III antiarrythymic drugs, according to its U.S. Food and Drug Administration (FDA)-approved labeling in the United States.
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Data on the frequency of the specific comorbid cardiac conditions from the fingolimod labeling are both limited and mixed. Three studies using hospital discharge records have assessed the risk of cardiac diseases in patients with MS relative to patients without MS. [12] [13] [14] The most recent of these studies, conducted by Christiansen et al. (2010) , utilized the Danish National Registry of Patients and reported an increased adjusted 1-year incidence rate ratio (IRR) of MI (IRR = 1.84, 95% confidence interval [CI] 1.28, 2.65), stroke (IRR = 1.95, 95% CI 1.42, 2.71), and heart failure (IRR = 1.92, 95% CI 1.27, 2.90). 12 But, Allen et al. (2008) reported a reduced risk of MI (odds ratio [OR] = 0.78, 95% CI 0.64, 0.96) and ischemic heart disease (OR = 0.58, 95% CI 0.51, 0.66) but an increased risk of stroke (OR = 1.66, 95% CI 1.33, 2.09) in an urban U.S. setting. 13 Finally, Fleming et al. (1994) reported a significantly reduced likelihood (P < 0.05) of MI, heart failure, angina, and cardiovascular disease among discharges for elderly patients insured by Medicare in the United States. 14 Given the limited data on the comorbid cardiac conditions that are contraindicated for fingolimod in patients with MS and the potential association between comorbidities and costs, All hospitalizations with a primary or secondary diagnosis of multiple sclerosis (ICD-9-CM 340.xx) n = 136,542
MS with Cardiac Condition
Primary or secondary diagnosis of a cardiac condition of interest n=12,504
MS with No Cardiac Condition
No primary or secondary diagnosis of a cardiac condition of interest n = 124,038 , and heart failure (428.xx). Identification of a cardiac condition was not limited, so a discharge could have more than 1 condition included in the results. The cardiac conditions selected were generally based on the contraindications in fingolimod's FDA-approved prescribing information; however, given the limitations of the dataset, it was not possible to identify all possible contraindications, including the use of antiarrythmic medications, the class of heart failure or whether heart failure required a hospitalization, Mobitz Type II second degree or third degree AV block or sick sinus syndrome unless patient has a pacemaker, or baseline QTc > 500ms.
Outcome Measures and Statistical Analysis
The main outcome measures were the frequency of comorbid cardiac conditions among all discharges with an MS diagnosis and the mean adjusted cost per discharge for the 2 study cohorts. The frequency of cardiac conditions was reported for all discharges stratified by year and diagnosis. The NIS data report charges, which represent the amount that the hospital charged for services and not the amount that the hospital services actually cost or receive in payment. To obtain adjusted costs per discharge, mean charges were converted to costs using a cost-to-charge ratio provided by the NIS. Regression models were used to predict costs and controlled for age, gender, payer type, presence of a comorbid cardiac condition, and length of stay. An incremental cost-effectiveness ratio was calculated for the cost per additional hospital day for the 2 cohorts. Costs are reported in 2010 dollars, and all analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
■■ Results
There were 39.9 million discharges in the dataset over the 5-year study period, with 136,542 discharges having a diagnosis of MS. Of these discharges with a diagnosis of MS, 9.2% (n = 12,504) had at least 1 comorbid cardiac condition of interest. The sample characteristics are shown in Table 1 .
The frequency of MS discharges with a comorbid cardiac condition remained stable throughout the 5-year study time period, ranging from 8.6% to 9.6% (Figure 2 ). Heart failure was the most common comorbid condition (59.4%), followed by MI (17.2%) and occlusion of cerebral arteries (12.4%). All of the other cardiac comorbidities were present in fewer than 10% of the discharges (Figure 3) .
The mean adjusted cost per discharge was significantly higher for the MS with cardiac condition cohort compared with the MS with no cardiac condition cohort after controlling for confounders ($17,623 vs. $11,663, P < 0.0001). The incremental cost per hospital day was $6,479 for the MS with cardiac condition cohort.
■■ Discussion
Cardiac conditions account for a large number of hospital discharges, regardless of MS status. Based on the National Hospital Discharge Survey, cardiac conditions (defined as acute MI, coronary atherosclerosis, ischemic heart disease, dysrhythmias, and congestive heart failure [CHF]) were second only to females with deliveries for hospitalizations in 2010. When specific conditions were assessed, CHF was by far the most common cardiac condition for hospitalizations. 
Frequency of CV Diagnoses in MS with Cardiac Condition Cohort (n = 12,504) a
Based on NIS data, CHF alone was the fourth most common principal diagnosis for hospital stays in 2010. 17 Our study defined the frequency of cardiac contraindications to fingolimod in U.S. hospital discharges with MS. While previous studies have assessed cardiac comorbidities in patients with MS, the objective of these previous studies was to compare the frequency relative to the general population, and their findings are largely mixed. 12 Regardless of the relative risk of cardiac comorbidities associated with MS compared with the general population, our findings show overlap in these conditions, and ours is the only study to examine the specific cardiac comorbidities in the fingolimod prescribing information within 1 study.
Our study also reported a higher mean adjusted cost per discharge when a cardiac disease is present, with an incremental cost per hospital day of $6,479 with a cardiac diagnosis. Given the high cost of MS and the emphasis on controlling health care costs, this evidence supports the need for intervention in patients with MS who also have a cardiac disease. Importantly, the most frequent cardiac conditions in this study were heart failure (59.4%) and MI (17.2%), both of which may be either modifiable or preventable. Therefore, screening patients with MS for these cardiac conditions could result in avoided hospitalizations and cost savings.
Limitations
This study has several limitations. First, as this study is a discharge-level analysis, there is no patient-specific identifier in the dataset. Therefore a given patient may have been double counted, resulting in an overestimation of the true frequency of MS and cardiac conditions. This limitation also prevented us from being able to match cohorts based on age, gender, and comorbid conditions, in order to conduct cleaner comparisons between the cohorts. Second, the comorbid cardiac conditions assessed in this study are likely to result in hospitalizations. Therefore, the overlap of cardiac disease and MS in this study may be higher than in an ambulatory population. Since we did not limit the cardiac conditions to the primary or secondary diagnosis fields (to ensure all conditions were captured), the results-particularly with regards to costs-should be interpreted with this in mind. The reason for admission has the capacity to greatly influence the costs associated with a hospitalization. However, the point of our study was to try to capture the frequency between MS and cardiac conditions, so we were generous with our inclusion criteria. Third, this study relied upon diagnoses reported in the discharge records, which are subject to miscoding or misclassification bias. Finally, we could not identify all contraindications to fingolimod in this study, given the limitations in the dataset, such as lack of prescription drug data. Similarly, we also could not assess whether or not immunomodulatory therapy was being used. Despite the limitations of this study, the NIS dataset used for this study is the largest hospital dataset in the United States. It is representative of the multiple payer types in the United States and drawn from a geographically representative area, allowing a large sample size.
■■ Conclusions
Comorbid cardiac conditions occurred in approximately 9% of hospitalizations of patients with MS. Health plans should give consideration to the overlapping presence of these diseases when determining coverage criteria for immunomodulatory therapies. Furthermore, comorbid cardiac conditions are associated with higher hospitalization costs in patients with MS as compared with those without a cardiac condition. Since MS is already a costly disease, clinical programs to screen patients with MS for cardiac disease or precursors to cardiac disease could result in avoided hospitalizations and reduced costs. Further research, including longitudinal and ambulatory data, is needed to assess the true prevalence of cardiac disease in patients with MS.
